163 results about "Hypoglycemic drugs" patented technology

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.

The invention provides camel milk active peptide and application thereof in preparation of drugs and edible products for treating and / or preventing diabetes mellitus. Two polypeptide compounds are obtained from papain enzymolysis products of fresh camel milk. Bioactivity evaluation shows that the polypeptide compound has remarkable protein tyrosine phospholipase 1B (PTP1B) inhibitory activity, can enhance insulin receptor sensitivity and promote hepatocyte glucose uptake, has patent medicine potential in the aspect of treating type II diabetes, and can be used for preparing medicines for treating type II diabetes. And a new material basis is provided for developing innovative medicines for treating type II diabetes and developing innovative PTP1B inhibitor hypoglycemic medicines.

The invention discloses a self-crosslinking hydrogel with a tertiary amine group and preparation and application thereof, and belongs to the field of biomedical polymer materials, the self-crosslinking hydrogel comprises aminophenylboronic acid modified oxidized glucan, tertiary amine compound modified oxidized glucan and a solvent medium; the preparation method comprises the following steps: dissolving amino phenylboronic acid modified oxidized dextran and tertiary amine compound modified oxidized dextran in a solvent medium, mixing, standing for a certain time, and carrying out self-crosslinking to obtain the self-crosslinking hydrogel with tertiary amine groups. A cross-linking point (phenylboronic acid) of the gel network is a response unit of glucose. In addition, the hydrogel can effectively avoid uncontrollable drug release caused by non-responsive factors, and the response release efficiency of the drug is improved; by loading the hypoglycemic drug insulin to be applied to the treatment research process of diabetes, the occurrence of hypoglycemia can be avoided, and meanwhile, the possibility is provided for realizing intelligent controlled release of insulin through blood glucose response.

The invention belongs to the technical field of plant active peptides, and particularly relates to a red kidney bean hypoglycemic active peptide and application thereof. The amino acid sequences of the hypoglycemic active peptide are FFGGPAF, SAKPFFSGL and PPGHPFVTF. The invention further discloses a preparation method of the hypoglycemic active peptide. FF, SL and PF for short. The polypeptide is prepared through enzymolysis of red kidney bean protein, and the polypeptide is identified by utilizing ultrafiltration separation and LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry); the hypoglycemic active peptides which are high in hypoglycemic effect, free of toxicity, carcinogenicity and sensitization and capable of being absorbed by human intestinal tracts are screened out through a bioinformatics method and molecular docking, then the screened hypoglycemic active peptides and alpha-glucosidase are subjected to molecular docking, and finally three hypoglycemic active peptides FF, SL and PF are screened out. The invention finds that the hypoglycemic active peptides FF, SL and PF have high inhibitory activity on alpha-glucosidase, can obviously promote glucose consumption of insulin resistance model cells, and can be used for preparing hypoglycemic drugs, food and health care products.

The invention discloses a polypeptide with DPP-IV (dipeptidyl peptidase-IV) inhibitory activity and application of the polypeptide. Pure peptides APFP and MPFP are obtained through a solid-phase synthesis method, the DPP-IV inhibition IC50 values of the pure peptides APFP and MPFP are measured to be 153.08 mu M and 296.50 mu M respectively, and the DPP-IV inhibition activity of the pure peptides APFP and MPFP is higher than that of partial fragments in the sequences of the pure peptides APFP and MPFP. The peptide fragments APFP and MPFP disclosed by the invention have relatively strong DPP-IV inhibitory activity, can be used for preparing hypoglycemic drugs or foods, and have wide application prospects in industrial application.

The invention discloses lactobacillus helveticus for producing DPP-IV (dipeptidyl peptidase-IV) inhibitory peptide and hypoglycemic goat milk and a preparation method thereof, goat milk is used as a raw material, and lactobacillus helveticus KD12 for producing the DPP-IV inhibitory peptide is used for fermenting the goat milk to obtain hypoglycemic lactobacillus fermented goat milk containing the DPP-IV inhibitory peptide. And drying the fermented goat milk to obtain the hypoglycemic lactic acid bacteria fermented goat milk powder containing the DPP-IV inhibitory peptide. Lactic acid bacteria of the hypoglycemic lactic acid bacteria fermented goat milk are inactivated to obtain hypoglycemic post-prebiotics goat milk, and the hypoglycemic post-prebiotics goat milk powder is obtained after the hypoglycemic post-prebiotics goat milk is concentrated and dried. The hypoglycemic goat dairy product provided by the invention has a relatively high DPP-IV inhibition rate, and can be used for inhibiting DPP-IV activity after consumers eat the hypoglycemic goat dairy product so as to reduce blood sugar and reduce the dosage of hypoglycemic drugs, so that side effects caused by the hypoglycemic drugs are reduced.

The invention belongs to the field of biological pharmacy, and relates to an alpha-amylase inhibitory peptide and application thereof. Specifically, the provided unreported peptide fragment LDKFLWT can effectively inhibit the activity of alpha-amylase, and animal experiments prove that the newly designed polypeptide has the effects of reducing blood sugar, reducing blood fat, improving insulin resistance and the like through polypeptide intervention; compared with a traditional hypoglycemic drug, the alpha-amylase inhibitory peptide disclosed by the invention has remarkable safety.

The present application relates to the technical field of microbial medicine, and particularly to a preparation method and application of indole diterpenoid compounds. Specifically, the extract of plant endophytic fungus F4a after solid fermentation culture is separated and purified to obtain indole diterpenoid compounds; the plant endophytic fungus F4a is a strain with the preservation number CCTCC NO: M 2012531. The indole diterpenoid compounds provided by the present application have significant antifeedant, insecticidal and hypotensive activities, and they can be used as ideal candidate compounds of antifeedants, insecticides or hypoglycemic drugs. The compounds can be produced through fungal fermentation, and the preparation method is simple, efficient and high in product purity. The present application has good application prospect.

The invention discloses a drug-loaded hydrogel microneedle and a preparation method and application thereof, and the drug-loaded hydrogel microneedle comprises drug-loaded nanoparticles comprising a protein hypoglycemic drug loaded on a phenylboronic acid modified cationic polymer; the hydrogel microneedle is prepared from methacrylic acid chitosan modified by natural polyphenol and a diol diacrylic acid polymer, the drug-loaded nanoparticles are loaded on the hydrogel microneedle. The drug-loaded hydrogel microneedle has excellent biocompatibility, can effectively reduce inflammatory response through a triple therapy strategy of breaking a bacterial biofilm and improving oxidative stress response and hyperglycemia level of a wound surface, can be used for delivering different types of protein hypoglycemic drugs for promoting wound healing, and can be applied to the field of medical treatment through intelligent drug delivery. The repairing of blood vessels and tissues of wound surfaces is promoted, and a series of problems of poor bioavailability, poor treatment effect and the like of the existing hydrogel dressing are effectively solved.

The application discloses a preparation method of ethanol extract of Drynaria Rhizome and application thereof. The method comprises the following steps: crushing and sieving Drynaria Rhizome, adding ethanol, reflux extraction, combining filtrates, vacuum concentration and drying, and thus the ethanol extract of Drynaria Rhizome is obtained. The in-vitro alpha-glucosidase enzyme inhibition experiment shows that the ethanol extract of Drynaria Rhizome has a significant inhibitory effect on alpha-glucosidase enzyme, and the IC 50 is about 142.68 μ g / mL. Therefore, the ethanol extract of Drynaria Rhizome can be used for preparing a hypoglycemic drug, health care product or functional food, and has a wide application prospect.

The invention discloses application of metformin to improvement of crop seed germination and stress resistance, the metformin is used as a widely used hypoglycemic drug, has a cross-species conservative metabolism regulation function, can activate an antioxidant defense system of plants, maintain K < + > / Na < + > balance in the plants, and can improve the survivability of crops in saline-alkali soil. After the metformin is adopted to treat the seeds, the germination rate and the germination potential of the seeds are obviously improved, the chlorophyll content, the peroxidase content, the soluble protein content and the like of seedlings are obviously increased, the malondialdehyde content is obviously reduced, and the stress resistance is obviously enhanced. The technology is low in treatment cost, simple to operate and obvious in effect.

The invention discloses a procyanidine trimer compound, which has a chemical structure as shown in the specification. The hypoglycemic potential of the compound is evaluated through an in-vitro enzyme inhibition experiment, and the result shows that the compound has a remarkable inhibition effect on alpha-amylase, has good water solubility, is derived from natural plant resources, is clear in structure and good in safety, and has a huge application prospect in development of novel natural-source hypoglycemic drugs.

The invention discloses lychee chitosan as well as an extraction method and application thereof. The lychee shell polysaccharide is successfully separated and purified from lychee shells through a series of processes such as hot water ultrasonic extraction, ethanol precipitation, deproteinization, ion exchange column chromatography and gel column chromatography. The lychee chitosan is heteropolysaccharide and comprises arabinose, galactose, glucose and galacturonic acid, and the molar mass ratio of the arabinose to the galactose to the glucose to the galacturonic acid is (27-29): (13-15): (13-15): (18-19). The lychee shell polysaccharide prepared by the method has good oil holding capacity and hygroscopicity, and due to the characteristics, the lychee shell polysaccharide can be used as a preparation auxiliary material and is widely applied to the fields of medicines, foods, health care products and cosmetics. In addition, the polysaccharide has a remarkable inhibition effect on alpha-amylase and alpha-glucosidase, and due to the characteristic, the polysaccharide has an extremely wide application prospect in the aspect of developing hypoglycemic drugs, functional foods and health-care products.

The present invention belongs to the technical field of hypoglycemic drugs, and specifically relates to a hypoglycemic pharmaceutical composition, a pharmaceutical preparation and a preparation method thereof. The hypoglycemic pharmaceutical composition and the pharmaceutical preparation comprise metformin hydrochloride, as well as a mixed granule of bitter melon extract and microcrystalline cellulose. The preparation method of the hypoglycemic pharmaceutical preparation comprises the following steps: Step 1, preparing a mixed granule of bitter melon extract and microcrystalline cellulose; Step 2, treating metformin hydrochloride and excipients for standby; Step 3, premixing the raw and auxiliary materials in Step 1 and Step 2; Step 4, sieving and sizing the powder premixed in Step 3; Step 5, adding a lubricant to the sized powder in Step 4 for total mixing; Step 6, tabletting and packaging the granules after total mixing in Step 5. By using the pharmaceutical composition or the pharmaceutical preparation of the present invention, it is possible to prevent and treat diabetes while reducing the incidence of gastrointestinal reactions caused by metformin hydrochloride.

The invention provides corn stigma polysaccharide, a preparation method thereof and application of the corn stigma polysaccharide in preparation of hypoglycemic drugs, and belongs to the technical field of plant polysaccharide extraction. The preparation method comprises the following steps: mixing corn stigma powder, ascorbic acid and water, adding pectinase into the mixed solution to carry out first enzymolysis, and adding cellulase and papain after 20-30 minutes to carry out second enzymolysis; after enzymolysis is completed, protein in enzymatic hydrolysate is removed, a corn stigma polysaccharide extracting solution is obtained, the corn stigma polysaccharide extracting solution is concentrated under reduced pressure, absolute ethyl alcohol is added for alcohol precipitation, then dialysis is conducted, and the corn stigma polysaccharide is obtained. The corn stigma polysaccharide prepared by the method has high yield, purity and hypoglycemic activity, and can be applied to preparation of hypoglycemic drugs.

The application discloses corn silk glucan, a structure formula of which is [→4)-β-D-Glcp-(1→]n, wherein n is 6-60, and a molecular weight range is 1-9.8 kDa. By extracting effective components in corn silk, an extract is obtained, the extract is precipitated by 30-90% ethanol, corn silk crude polysaccharide is obtained, and after the corn silk crude polysaccharide is dissolved, the corn silk crude polysaccharide is sequentially subjected to biological membrane dialysis, ion exchange resin column and HPLC-ELSD separation and purification, and corn silk glucan is obtained. The corn silk glucan and zeaxanthin are compounded to form a glucan compound, the glucan compound can stabilize insulin and improve the activity of the insulin in mouse islet cells, and the glucan compound has 2-5 times stronger hypoglycemic activity than that of zeaxanthin alone, and therefore, the glucan compound has important significance for researching new hypoglycemic drugs or health-care food for assisting hypoglycemia.

The present invention discloses a device for facilitating the disassembly of the needle of a hypoglycemic drug injection pen and a disassembly method thereof, belonging to the technical field of medical devices. It includes an injection pen, and the injection pen is an intelligent hypoglycemic drug injection pen, and a hypoglycemic drug injection pen cap. An aseptic disassembly device for disassembling the needle of the intelligent hypoglycemic drug injection pen is provided inside the intelligent hypoglycemic drug injection pen cap. An aseptic disinfection device for disinfecting the tip of the intelligent hypoglycemic drug injection pen and the injection site required by the human body is also provided inside the intelligent hypoglycemic drug injection pen cap. This device can uniformly and comprehensively disinfect the tip of the drug injection pen under aseptic conditions, and can, under aseptic conditions, remove the needle from the tip of the drug injection pen, avoiding the risk of the needle stabbing people during disassembly and causing bacterial infection. At the same time, it can also disinfect the injection site required by the patient, realizing the integrated design of the injection pen, the needle disassembly device, the disinfection tool and the injection pen cap.

This invention provides a mulberry leaf and wolfberry composition, comprising aqueous extracts of wolfberry, mulberry leaves, astragalus, yam, kudzu root, and green tea. This invention also provides oral preparations and food products containing this composition. Furthermore, this invention provides the application of the composition or oral preparation in the preparation of health foods that help maintain healthy blood sugar levels and hypoglycemic drugs. The composition provided by this invention has the effect of lowering blood sugar, and the selected raw materials are highly safe, have few toxic side effects, and are widely available, possessing significant market value and development prospects.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

The present application relates to soybean active peptides with hypoglycemic activity and a preparation method and application thereof, and belongs to the technical field of active peptide proteins. The active peptides are selected from SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4; the amino acid sequences of the SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 are respectively: GPFGT, DSRPLY, SGFGKL, IFGM. The soybean active peptides of the present application are verified by experiments to have hypoglycemic activity, are safe, have no toxic side effects, can be used as functional ingredients in hypoglycemic drugs, and have good potential and application prospects.

The present application relates to a kind of preparation methods of white birch alcohols-pectin nanoparticles loaded with peony polyphenol: 1) preparation peony polyphenol: 2) preparation pectin: 3) preparation white birch alcohols-pectin nanoparticles: white birch alcohols and peony seed pectin are dissolved in DMSO, N,N-dimethylaminopyridine is added as catalyst, reaction is carried out at room temperature for 8-16h, dialysis, freeze-drying is obtained white birch alcohols-pectin nanoparticles;4) white birch alcohols-pectin nanoparticles and peony polyphenol are dissolved in appropriate amount of DMSO according to proportion, then drop into distilled water under stirring, dialysis, freeze-drying, white birch alcohols-pectin nanoparticles loaded with peony polyphenol are obtained.The present application is connected by ester bond using carboxyl on pectin and hydroxyl on white birch alcohols, forms nano delivery carrier, then with peony polyphenol, forms water-soluble white birch alcohols-pectin / peony polyphenol nanoparticles, which can be used for preparing antitumor or hypoglycemic drug.

The invention discloses an extraction method of ophiopogon japonicus polysaccharide, which comprises the following steps: (1) drying ophiopogon japonicus, crushing and sieving to obtain ophiopogon japonicus powder; (2) mixing the radix ophiopogonis powder and water in a weight ratio of 1: (15-20), sterilizing, inoculating pediococcus pentosaceus, lactobacillus plantarum and lactobacillus fermentum mixed bacteria, fermenting and culturing at the temperature of 30-40 DEG C, adjusting the pH value to 5-6, and culturing for 10-15 hours; (3) performing centrifugal solid-liquid separation on the fermentation liquor obtained in the step (2), discarding solids, and collecting supernate; (4) removing protein through an isoelectric point method, adjusting the pH value to 2.5, centrifuging when floccules appear, and collecting supernate; (5) adjusting the pH value of the liquid to be neutral, and adding macroporous resin to dynamically adsorb pigment substances; (6) adding absolute ethyl alcohol, and carrying out alcohol precipitation overnight; and (7) collecting the precipitate, redissolving, dialyzing, collecting the dialyzed solution, and freeze-drying to obtain the ophiopogon japonicus polysaccharide. The ophiopogon japonicus polysaccharide is extracted by using a combined fermentation method of pediococcus pentosaceus, lactobacillus plantarum and lactobacillus fermentum, and the extraction efficiency is high.

The invention belongs to the technical field of traditional Chinese medicine, and relates to polygonum cuspidatum homogeneous polysaccharide and a preparation method and application thereof.The polygonum cuspidatum homogeneous polysaccharide is mainly composed of galacturonic acid, rhamnose, galactose, glucuronic acid, glucose, mannose, xylose and glucuronide amine according to the molar ratio of 41.967: 24.624: 17.951: 5.427: 4.59: 3.501: 1.236: 0.358, and the weight-average molecular weight of the polygonum cuspidatum homogeneous polysaccharide is 26.57 kDa. The polygonum cuspidatum homogeneous polysaccharide is fixed in component, high in yield, good in hypoglycemic effect and good in safety, and a basis is provided for development of innovative hypoglycemic drugs.

The invention belongs to the technical field of medicines, and discloses a depleted acid carbon glycoside compound derived from fungi and an application of the depleted acid carbon glycoside compound. The invention focuses on intensive study on the depleted acid carbon glycoside compound and the antibacterial and hypoglycemic effects thereof. The depleted acid carbon glycoside compound provided by the invention has potential application value in the aspect of preparing medicines for preventing or treating bacteria or reducing blood sugar.

The invention relates to the technical field of medicines, in particular to beta-dihydroagarofuran type sesquiterpenes, a preparation method and application, and the structural formula of the beta-dihydroagarofuran type sesquiterpenes is shown as a formula I: # imgabs0 #. The chemical structure and physicochemical properties of the beta-dihydroagarofuran type sesquiterpenoids are confirmed through nuclear magnetic resonance, mass spectrum, infrared and other determination methods, and the pharmacological activity of the beta-dihydroagarofuran type sesquiterpenoids is verified through cell experiments. The novel beta-dihydroagarofuran type sesquiterpenoids have an obvious inhibition effect on SGLT-2, show excellent hypoglycemic activity and can be used as a lead compound for developing a novel hypoglycemic drug.

The invention discloses a traditional Chinese medicine capsule for treating diabetes and a preparation method thereof, and belongs to the technical field of medicine preparation. The capsule is composed of main materials and auxiliary materials. The main materials are composed of 23-27 g of radix astragali, 23-27 g of radix puerariae, 18-22 g of rhizoma polygonati, 18-22 g of Chinese yam, 13-17 g of radix scrophulariae, 13-17 g of radix rehmanniae praeparata, 13-17 g of radix salviae miltiorrhizae, 8-12 g of rhizoma coptidis, 8-12 g of silkworm excrement, 8-12 g of rhizoma polygoni cuspidati, 7-9 g of liquorice and 5-7 g of fructus momordicae. The auxiliary material consists of lactose, microcrystalline cellulose and superfine silica powder in a mass ratio of 10: 10: 1, and the total weight of the auxiliary material is 210g. Double-section countercurrent extraction and low-temperature belt type drying are adopted, the retention rate of effective components is increased, the content of berberine and the content of salvianolic acid B are increased by 18% and 22% respectively, in addition, particle size grading compatibility is adopted, quick release and gastrointestinal tolerance are both considered, artificial sweeteners or chemical hypoglycemic drugs are not additionally added to the finished product, and the finished product conforms to human body metabolic motility.

The application provides a construction method of a cell model for screening hypoglycemic drugs, and belongs to the technical field of biotechnology.The method provided by the application comprises the following steps: cell verification, vector construction and plasmid extraction, cell electroporation, drug screening, stable strain amplification and Q-PCR verification.The application successfully constructs a stable fluorescence reporter model (Min6-ins2>EGFP) based on Min6 cells, and verifies the specificity and sensitivity of the model to insulin secretion promoting drugs through positive drug verification.The model is simple to operate, can be monitored in real time, is suitable for high-throughput screening, can be effectively used for hypoglycemic activity evaluation of complex components such as chemical drugs and traditional Chinese medicines, and provides a reliable tool for early screening of hypoglycemic drugs.

A Smad5 mutant and uses thereof in the prevention and treatment of diabetes. The amino acid sequence of the Smad5 mutant is as shown in SEQ NO ID:1. The invention further relates to a nucleic acid encoding the Smad5 mutant, a recombinant expression vector containing the nucleic acid, and a transformant. The uses also comprise uses of the nucleic acid, the recombinant expression vector containing the nucleic acid, and the transformant in the preparation of a medicament for preventing and / or treating diabetes. The Smad5 mutant can improve symptoms of type 1 and type 2 diabetes in vivo, and, compared with conventional oral hypoglycemic drugs, has no toxic or side effects and does not cause damage to the liver or kidneys of patients. In addition, the invention relates to a reagent for regulating acid-base balance, comprising alkaline drinking water containing baking soda; the reagent can lower blood glucose, alleviate diabetic symptoms, and is more economical and convenient for patients to use.